In drug development, where timelines are long, costs high, and bets fail, any tool that helps reduce risk is worth keeping. But only if were honest about what it cant do yet.
Read more at: The Molecule or the Method? Inside Biotech’s Reckoning with AI | Shared Everything From VAST
What are your thoughts? Did you learn something new? Do you agree with this take?